VTYX
Ventyx Biosciences, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website ventyxbio.com
- Employees(FY) 99
- ISIN US92332V1070
Performance
+5.58%
1W
-0.63%
1M
+92.28%
3M
+100.42%
6M
+91.5%
YTD
-86.39%
1Y
Profile
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Technical Analysis of VTYX 2024-05-10
Overview:
In analyzing the technical indicators for VTYX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for informed decisio...
Recent News & Updates
- 2024-05-16 04:05
- 2024-05-15 23:23
- 2024-05-15 20:00
- 2024-05-13 09:02
- 2024-05-12 22:37
- 2024-05-09 08:59
- 2024-05-09 04:01
- 2024-05-02 04:05
- 2024-04-30 00:00
- 2024-04-16 20:45
- 2024-04-16 17:45
- 2024-04-15 01:15
- 2024-03-26 18:20
- 2024-03-19 17:45
- 2024-03-18 06:02
- 2024-03-11 07:00
- 2024-03-10 19:29
- 2024-03-10 19:00
- 2024-03-07 08:52
- 2024-03-07 08:00
- 2024-03-06 19:00
- 2024-03-06 08:00
- 2024-03-05 19:00
- 2024-03-04 08:00
- 2024-03-03 19:00
- 2024-02-27 16:01
- 2024-02-27 03:01
- 2024-02-22 07:00
- 2024-02-21 18:00
- 2024-02-21 03:09
Page 1 of 4
previousnext